← Back to catalogue

AlexiFuse Synthetic Foam Putty

FDA UDI

Class II (US FDA UDI)

by Berkeley Advanced Biomaterials

Identity

Trade Name
AlexiFuse Synthetic Foam Putty FDA UDI
Generic Name
Bone matrix implant, composite FDA UDI
Device Name
AlexiFuse Synthetic Foam Putty is a sterile bone graft composed of purified fibrillar Type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. AlexiFuse Synthetic Foam Putty is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30 ml. FDA UDI
Model / Reference
AB-3453 FDA UDI
Description
AlexiFuse Synthetic Foam Putty is a sterile bone graft composed of purified fibrillar Type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. AlexiFuse Synthetic Foam Putty is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30 ml. FDA UDI

Identifiers

Catalog Number
AB-3453 FDA UDI
Primary DI / UDI-DI
00816125024872 FDA UDI
510(k) Number
K092046 FDA UDI
FDA Product Code
MQV FDA UDI
GMDN Term
Bone matrix implant, composite FDA UDI

Classification

Device Class
Class II FDA UDI
Regulation Number
888.3045 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

Yes

FDA UDI

Single Use

Yes

FDA UDI

Implantable

Yes

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

Yes

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

Yes

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

No

FDA UDI

Category: Bone matrix implant, composite

AlexiFuse Synthetic Foam Putty by Berkeley Advanced Biomaterials — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Bone matrix implant, composite.

Cleared under the same submission

K092046 also covers:

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Manufacturer
Berkeley Advanced Biomaterials

Sources (1)

  • FDA UDI aeb0258a-e8fd-42d1-a82b-7c32a75eabd5 35 fields · synced May 29, 2026